Abstract 565P
Background
The incidence of early-onset colon cancer (early-onset CC, age <50 years (yrs)) is rising with limited data on its clinical and molecular characteristics. We analyzed a real-world cohort of the AIO ColoPredict Plus (CPP) Registry.
Methods
CPP collects data and tissue from patients (pts) with CC UICC stage I-III. Clinical and molecular characteristics were assessed comparing pts <50yrs with pts 50+ using student’s Test and Fishers exact test. Disease-free survival (DFS) rate at 3 yrs was reported. Comorbidity was assessed by Charlson comorbidity index (CCI). Median follow-up was 28.1 months.
Results
Out of 9215 pts 479 (5%) had early-onset CC (median age 44 yrs (22-49) vs. 72 yrs (50-100) in late-onset CC). There were no significant differences regarding sex or BMI. Younger pts had less comorbidities (CCI 0: 91%) than older pts. (CCI 0: 60%, p <0.001). Interestingly, younger patients had larger tumors (p=0.045), more often lymph node metastases (p=0.002) and thus higher UICC stages (p<0,001). Tumor localization was predominantly left-sided in early- (53%) and right-sided in late-onset CC (61%, p<0,001). Younger pts more often received adjuvant chemotherapy (p<0,001) and more frequently oxaliplatin combinations (p<0,001). Mutational analysis was available in 5045 pts, 5% (264 pts) with early-onset CC. No significant difference in K- or N-RAS mutations or MSI were detected. The KRAS subtype p.G12C and BRAF mutations were significantly less prevalent in early-onset compared to late-onset CC (p=0,03 and p<0,01). Younger pts had a better 3 yrs DFS rate.
Conclusions
Pts with early-onset CC in our unique real-world cohort are more often UICC stage III with left primary tumors and better DFS. They also display distinct molecular features which should be considered when making treatment decisions.
Clinical trial identification
DRKS00004305.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Roche, BioNtech.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
518P - Artificial intelligence real-world applications in pediatric neuro-oncology: The AICCELERATE project
Presenter: Federica D'Antonio
Session: Poster session 10
519P - The landscape of PDGFRA mutation in Chinese patients with glioma
Presenter: Qiang Lv
Session: Poster session 10
520P - Copy number variation spectrum analysis of primary glioblastoma
Presenter: Chuandong Cheng
Session: Poster session 10
521P - Deciphering a three-miRNA signature as a prognostic biomarker in glioma patients: Correlation with DFS and OS
Presenter: Ana Belen Diaz Mendez
Session: Poster session 10
522P - Galectin 3 binding protein as potential biomarker in glioma diagnosis
Presenter: Rashmi Rana
Session: Poster session 10
523P - Analysis of DNA damage response (DDR) gene expression as a prognostic factor for glioblastoma patient mortality
Presenter: Alessia-Tara Droesse
Session: Poster session 10
524P - Cell line study of nucleosome-based biomarkers in the diagnosis and detection of relapses in glioblastoma
Presenter: Jonathan Decarpentrie
Session: Poster session 10
525P - Immuno markers in newly glioblastoma patients underwent Stupp protocol after neurosurgery
Presenter: Lorena Gurrieri
Session: Poster session 10
526P - In silico evaluation of the mutational profile of glioblastomas with high expression of PD1, CTLA4 and LAG3 identifies the ERBB-PI3K pathway as a druggable vulnerability target
Presenter: Cristina Saiz-Ladera
Session: Poster session 10
527P - Targetable gene fusions and other alterations in central nervous system tumors assessed by RNA and DNA-based next-generation sequencing
Presenter: LEIMING WANG
Session: Poster session 10